Surg­ing ahead in the RSV race, Pfiz­er buys out a PhII play­er in $525M M&A pact

Right on the heels of back-to-back break­through ther­a­py des­ig­na­tions for its lead RSV vac­cine, Pfiz­er is wa­ger­ing up to $525 mil­lion on a biotech buy­out that in­jects new RSV as­sets in­to its pipeline.

Pfiz­er is snap­ping up Re­Vi­ral af­ter in­spect­ing mid-stage da­ta for sisuna­tovir, an oral drug that blocks the fu­sion of RSV with host cells. And there’s more.

In their state­ment, Pfiz­er not­ed:

Sisuna­tovir sig­nif­i­cant­ly re­duced vi­ral load in a phase 2 RSV hu­man chal­lenge study in healthy adults and is cur­rent­ly in Phase 2 clin­i­cal de­vel­op­ment in in­fants. The de­vel­op­ment pro­gram for sisuna­tovir is ex­pect­ed to con­tin­ue in both adult and pe­di­atric pop­u­la­tions. A sec­ond pro­gram is fo­cused on the in­hi­bi­tion of RSV repli­ca­tion tar­get­ing the vi­ral N pro­tein. The lead can­di­date in this pro­gram is cur­rent­ly in Phase 1 clin­i­cal de­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER